235 results on '"Yun-Fei, Xia"'
Search Results
202. Abstract 570: Radiation resistance of orthotopic glioblastoma xenografts is mediated by increasing CD133+ cell fraction, mobilizing G0 cells into G1 phase, and activating self-renewal and mesenchymal genes
203. Prognosis Comparison and Therapeutic Considerations between Primary Nasopharyngeal B- and T/NK-cell Non-Hodgkin's Lymphomas at Early Stage: A Study of 136 Cases in South China
204. Role of Radiotherapy and Prognosis Analyses in Patients with Early Stage Extranodal Nasal Type NK/T-cell Lymphoma Treated Predominantly with Initial Chemotherapy
205. Continuous fall in hemoglobin level is a poor prognostic factor in patients with nasopharyngeal carcinoma treated with radiotherapy
206. Preliminary Results of Concurrent Chemoradiation Therapy in Patients with Early Stage Extranodal Nasal Type NK/T-cell Lymphoma
207. Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients.
208. Expression of NPCM correlates with radiosensitivity and metastasis in nasopharyngeal carcinoma
209. The preliminary research on the risk factors of the Ib level lymphatic nodes metastasis in recurrent nasopharyngeal carcinoma
210. Expression and clinical significance of DNA-Pk in nasopharyngeal carcinoma
211. Preliminary dosimetric investigation of planning scheme for local advanced nasopharyngeal carcinoma with C-shaped target in three-dimensional treatment planning system
212. Alternative endpoints to the 5-year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients.
213. Prognostic significance and therapeuticimplications of centromere protein F expressionin human nasopharyngeal carcinoma.
214. Quality of life of nasopharyngeal carcinoma survivors in Mainland China.
215. PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Clinical Trial.
216. A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
217. Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients
218. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma
219. A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
220. A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC
221. Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical Study
222. An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
223. Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma
224. Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
225. Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma
226. CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy
227. Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma
228. A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC
229. Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients
230. A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
231. A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
232. A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases
233. Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
234. Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
235. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.